|
|
Volumn 104, Issue 9, 2012, Pages 649-652
|
|
Macrophages: cancer therapy's double-edged sword.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CCL2 PROTEIN, HUMAN;
CD68 ANTIGEN, HUMAN;
COLONY STIMULATING FACTOR 1;
DIFFERENTIATION ANTIGEN;
LEUKOCYTE ANTIGEN;
MONOCYTE CHEMOTACTIC PROTEIN 1;
NEW DRUG;
ANIMAL;
CLINICAL TRIAL (TOPIC);
DISEASE COURSE;
DRUG ANTAGONISM;
DRUG EFFECT;
HUMAN;
IMMUNOLOGY;
MACROPHAGE;
METABOLISM;
METHODOLOGY;
MOLECULARLY TARGETED THERAPY;
MOUSE;
NEOPLASM;
NOTE;
PANCREAS TUMOR;
PREDICTIVE VALUE;
PROGNOSIS;
T LYMPHOCYTE;
ANIMALS;
ANTIGENS, CD;
ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC;
ANTINEOPLASTIC AGENTS;
CHEMOKINE CCL2;
CLINICAL TRIALS AS TOPIC;
DISEASE PROGRESSION;
DRUGS, INVESTIGATIONAL;
HUMANS;
MACROPHAGE COLONY-STIMULATING FACTOR;
MACROPHAGES;
MICE;
MOLECULAR TARGETED THERAPY;
NEOPLASMS;
PANCREATIC NEOPLASMS;
PREDICTIVE VALUE OF TESTS;
PROGNOSIS;
T-LYMPHOCYTES;
|
|
EID: 84873031574
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djs235 Document Type: Note |
|
Times cited : (15)
|
|
References (0)
|
